BIO International


Chemestmed was thrilled to participate in the BIO International Convention in San Diego from June 3-6.

Our CSO, Dr. Sigrid Selberg, along with members of our advisory board, Dr. Esko Kankuri and Professor Andres Merits, presented our groundbreaking results on unique proprietary RNA m6A activators targeting neurodegeneration, neuropsychiatric, and metabolic disorders, including obesity and diabetes. Notably, our innovative RNA m6A activation technology opens new avenues for developing drugs for various RNA m6A deficient pathologies such as T2DM, Alzheimer’s disease, neuropathic pain, epilepsy, and more.

We are actively seeking partnerships for further development of our compounds, with the goal of advancing to the clinical phase. If you’re interested in collaborating, let’s connect!